X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs NOVARTIS - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD NOVARTIS ORCHID PHARMA LTD/
NOVARTIS
 
P/E (TTM) x -0.5 360.9 - View Chart
P/BV x 0.4 17.8 2.0% View Chart
Dividend Yield % 0.0 1.6 -  

Financials

 ORCHID PHARMA LTD   NOVARTIS
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
NOVARTIS
Mar-16
ORCHID PHARMA LTD/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs194982 19.8%   
Low Rs35556 6.3%   
Sales per share (Unadj.) Rs276.5252.9 109.3%  
Earnings per share (Unadj.) Rs-79.262.1 -127.5%  
Cash flow per share (Unadj.) Rs-43.563.3 -68.7%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs53.9363.6 14.8%  
Shares outstanding (eoy) m70.4531.96 220.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.43.0 13.6%   
Avg P/E ratio x-1.412.4 -11.7%  
P/CF ratio (eoy) x-2.612.2 -21.7%  
Price / Book Value ratio x2.12.1 100.4%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m8,06724,580 32.8%   
No. of employees `0002.80.8 372.3%   
Total wages/salary Rs m2,5271,801 140.3%   
Avg. sales/employee Rs Th6,956.110,748.9 64.7%   
Avg. wages/employee Rs Th902.52,395.2 37.7%   
Avg. net profit/employee Rs Th-1,993.02,641.1 -75.5%   
INCOME DATA
Net Sales Rs m19,4778,083 241.0%  
Other income Rs m407829 49.1%   
Total revenues Rs m19,8848,913 223.1%   
Gross profit Rs m1,103234 470.8%  
Depreciation Rs m2,51937 6,864.3%   
Interest Rs m5,2272 290,377.8%   
Profit before tax Rs m-6,2361,025 -608.4%   
Minority Interest Rs m200-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m5111,696 30.1%   
Tax Rs m-125752 -16.6%   
Profit after tax Rs m-5,5801,986 -281.0%  
Gross profit margin %5.72.9 195.4%  
Effective tax rate %2.073.4 2.7%   
Net profit margin %-28.724.6 -116.6%  
BALANCE SHEET DATA
Current assets Rs m11,01412,678 86.9%   
Current liabilities Rs m32,0602,433 1,317.7%   
Net working cap to sales %-108.1126.7 -85.3%  
Current ratio x0.35.2 6.6%  
Inventory Days Days9533 290.2%  
Debtors Days Days3422 149.2%  
Net fixed assets Rs m29,44069 42,543.2%   
Share capital Rs m705160 440.9%   
"Free" reserves Rs m2,04311,460 17.8%   
Net worth Rs m3,80011,621 32.7%   
Long term debt Rs m9,0180-   
Total assets Rs m46,51014,400 323.0%  
Interest coverage x-0.2570.5 -0.0%   
Debt to equity ratio x2.40-  
Sales to assets ratio x0.40.6 74.6%   
Return on assets %-0.813.8 -5.5%  
Return on equity %-146.917.1 -859.3%  
Return on capital %-3.723.6 -15.8%  
Exports to sales %37.90.7 5,086.0%   
Imports to sales %22.618.6 121.7%   
Exports (fob) Rs m7,37860 12,255.1%   
Imports (cif) Rs m4,4061,503 293.2%   
Fx inflow Rs m7,513186 4,032.9%   
Fx outflow Rs m5,6491,821 310.2%   
Net fx Rs m1,865-1,635 -114.1%   
CASH FLOW
From Operations Rs m1,6822,531 66.4%  
From Investments Rs m-9,860-8,270 119.2%  
From Financial Activity Rs m6,644-386 -1,722.5%  
Net Cashflow Rs m-1,535-6,125 25.1%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.6 2.0 230.0%  
FIIs % 3.3 1.6 206.3%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 21.5 257.2%  
Shareholders   84,811 41,647 203.6%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   ALEMBIC LTD  SUN PHARMA  PFIZER  FDC LTD.  SHASUN PHARMA  

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Feb 22, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS